A new study in the Journal of Critical Care suggests that a test manufactured by Inverness Medical Innovations Inc. can predict acute kidney injury for patients admitted into an ICU unit.
The study, which involved 88 patients observed over one month, was conducted by researchers at the University Hospital of Clermont-Ferrand, France.
The investigators studied blood samples collected during admissions by critically ill patients using Inverness’ Triage NGAL Test to see if plasma neutrophil gelatinase-associated lipocalin (pNGAL) could be used as a predictor of acute kidney injury. The study concluded that pNGAL was an accurate biomarker for AKI in adult ICU patients.
Most patients admitted into the ICU suffer from some form of kidney injury, which can result in kidney failure if it’s not caught in time.
The Triage NGAL Test is part of Inverness’ professional products unit, which makes diagnostic tests for several disease types, including the company’s BinaxNOW influenza test.